Name | Type | Posted | Actions |
|---|---|---|---|
A0001 Price List -Komzifti - Leukemia and Lynphoma Agents - AML.xlsx | XLSX | Dec 17, 2025 | |
A0001 HT9402-26-Q-9103.pdf | Dec 17, 2025 | ||
DoD Formulary Placement of FDA Newly Approved Drugs.pdf | Dec 11, 2025 | ||
Price List - Starjemza - TIBs - IL-23.xlsx | XLSX | Dec 11, 2025 | |
Price List - Redemplo - Antilipidemics-2 - NA.xlsx | XLSX | Dec 11, 2025 | |
Price List - Lasix ONYU - Diuretics - NA.xlsx | XLSX | Dec 11, 2025 | |
health.mil/pandt | LINK | Dec 11, 2025 | |
Price List -Javadin - Antihypertensive Agents - NA.xlsx | XLSX | Dec 11, 2025 | |
Price List -Hyrnuo - Lung Cancer - HER2.xlsx | XLSX | Dec 11, 2025 | |
RFQ HT9402-26-Q-9103 NAD.pdf | Dec 11, 2025 | ||
Price List -Komzifti - Oncological Agents - NA.xlsx | XLSX | Dec 11, 2025 | |
Price Appendix FAQ NAD.pdf | Dec 11, 2025 |
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Contact and place of performance
Tracy Banks
San Antonio, TX 78230
USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical e...
View morea. Hyrnuo - Lung Cancer - HER2+
b. Javadin - Antihypertensive Agents - N/A
c. Komzifti - Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia
d. Lasix ONYU - Diuretics - N/A
e. Redemplo - Antilipidemics-2 - N/A
f. Starjemza - Targeted Immunomodulatory Biologics - Interleukin 23
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9103.
Pre-quotation teleconference is on December 17, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
The Defense Health Agency Aurora, under the TRICARE Management Activity, is soliciting quotations for pharmaceutical agents to support the Department of Defense (DoD) Pharmacy Uniform Formulary. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the DoD Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of drugs to determine their classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. This solicitation seeks to establish Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) agreements for newly approved drugs across various therapeutic classes, including lung cancer, antihypertensive agents, leukemia and lymphoma agents, diuretics, antilipidemics, and targeted immunomodulatory biologics.
Solicitation HT9402-26-Q-9103 is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals. The procurement involves specific evaluations of products such as Hyrnuo, Javadin, Komzifti, Lasix ONYU, Redemplo, and Starjemza. Performance is centered in San Antonio, Texas, and the notice includes 12 attachments providing price lists, formulary placement guidance, and formal RFQ documentation.
The response deadline for this solicitation is January 5, 2026. Submissions must include responses to clinical questions as specified in the RFQ, which was published on December 11, 2025, and updated on December 17, 2025. Administrative and technical coordination is managed by point of contact Tracy Banks. Award determinations will be based on the forthcoming February 2026 P&T Committee decisions regarding the relative effectiveness and cost of the pharmaceutical agents within their respective drug classes.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.